March 9 (Reuters) – Bristol Myers Squibb on Monday said its experimental cancer drug met the main goal of a late-stage study. The oral drug mezigdomide was tested in combination with carfilzomib and dexamethasone to treat multiple myeloma, a rare blood cancer. The combination therapy showed a significant improvement in survival without the disease worsening […]
Health
Bristol’s cancer drug meets main goal in late-stage trial
Audio By Carbonatix
March 9 (Reuters) – Bristol Myers Squibb on Monday said its experimental cancer drug met the main goal of a late-stage study.
The oral drug mezigdomide was tested in combination with carfilzomib and dexamethasone to treat multiple myeloma, a rare blood cancer.
The combination therapy showed a significant improvement in survival without the disease worsening compared to carfilzomib and dexamethasone alone.
(Reporting by Sneha S K in Bengaluru; Editing by Vijay Kishore)